Taysha Gene Therapies TSHA 深 沪
等待开盘 10-22 09:30:00 美东时间
5.2752
+0.555
+11.76%
华盛通- 最 高5.33
- 今 开4.93
- 成交量 360.15万股
- 最 低 4.81
- 昨 收 4.72
- 总市值 14.40亿
- 52周最高 5.5082
- 市盈率 静 --
- 换手率 1.32%
- 52周最低 1.05
- 委 比 24.96%
- 总股本 2.73亿
- 历史最高 33.35
- 量 比 0.82
- 振 幅 11.02%
- 历史最低 0.50
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Taysha Gene Therapies Regains Full Rights To Its Lead TSHA-102 Program In Clinical Evaluation For Rett Syndrome; TSHA-102 Has Demonstrated Compelling Part A REVEAL Phase 1/2 Safety And Efficacy Data, Received FDA Breakthrough Therapy Designation And Is Advancing With A Clear Path To Potential Registration
DALLAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
10-17 04:06
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
<p>Taysha Gene Therapies announced the expiration of its 2022 Option Agreement with Astellas Pharma, regaining full rights to its TSHA-102 program for Rett syndrome. The program has shown promising safety and efficacy data, receiving FDA Breakthrough Therapy designation. dosing of the first patient in the pivotal REVEAL trial is scheduled this quarter. Taysha now has full strategic flexibility to advance TSHA-102 towards potential commercializati...
10-16 20:01
Taysha Gene Therapies Presents Promising TSHA-102 Data
Taysha Gene Therapies ( ($TSHA) ) just unveiled an announcement. On October 9, ...
10-09 20:44
Taysha Gene Announces Results From Supplemental Data Analysis From Part A Of REVEAL Phase 1/2 Adult/Adolescent And Pediatric Trials Evaluating TSHA-102 In Females With Rett Syndrome At CNS Annual Meeting
Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by
10-09 20:04
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Dallas, Oct. 09, 2025 (GLOBE NEWSWIRE) – Taysha Gene Therapies (TSHA) announced new supportive data from Part A of the REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome. 100% of patients (N=10) achieved ≥ one developmental milestone, with 22 milestones and 165 additional skills/improvements observed. Analysis using validated scales highlighted consistent functional gains in communication, fine motor, gross motor, and autonomic function. These...
10-09 12:00
美股周涨跌榜 | “氢能第一股”再度爆发！普拉格能源周涨超60%；Lithium Americas周涨超42%
“氢能第一股”再度爆发！普拉格能源周涨超60%，已连涨四周；Lithium Americas周涨超42%，获美国能源部入股；TSHA周涨超46%，试验性治疗获FDA突破性疗法认定>>
10-06 15:15
美股牛股 | TSHA飙升超53%，试验性治疗获FDA突破性疗法认定；嘉楠科技大涨近27%
TSHA飙升超53%，试验性治疗获FDA突破性疗法认定；嘉楠科技大涨近27%，比特币重返12万美元叠加公司获得大规模矿机订单；ONDS涨26%，获国防无人机订单>>
10-03 19:10
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
SoundHound AI Stock Is Surging: What's Going On?
SoundHound AI Inc (NASDAQ:SOUN) shares are trading sharply higher Thursday. The stock may be benefiting from renewed investor attention to the company's recent industry recognition and strong revenue momentum.
10-03 01:44
